1. Home
  2. KINS vs MDWD Comparison

KINS vs MDWD Comparison

Compare KINS & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KINS

Kingstone Companies Inc.

HOLD

Current Price

$17.29

Market Cap

209.0M

Sector

Finance

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$18.68

Market Cap

238.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KINS
MDWD
Founded
1886
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
209.0M
238.5M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
KINS
MDWD
Price
$17.29
$18.68
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$37.50
AVG Volume (30 Days)
135.5K
78.6K
Earning Date
02-23-2026
11-20-2025
Dividend Yield
1.16%
N/A
EPS Growth
69.11
N/A
EPS
2.26
N/A
Revenue
$198,583,138.00
$20,932,000.00
Revenue This Year
$37.94
$15.89
Revenue Next Year
$8.63
$25.33
P/E Ratio
$7.64
N/A
Revenue Growth
32.70
6.15
52 Week Low
$13.08
$14.14
52 Week High
$22.40
$22.51

Technical Indicators

Market Signals
Indicator
KINS
MDWD
Relative Strength Index (RSI) 64.38 51.69
Support Level $15.89 $18.55
Resistance Level $17.56 $19.70
Average True Range (ATR) 0.55 0.59
MACD -0.04 0.02
Stochastic Oscillator 69.00 38.06

Price Performance

Historical Comparison
KINS
MDWD

About KINS Kingstone Companies Inc.

Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: